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The answer for the question posed in the title is: considering
a clinical applicability, we are standing in the very beginning.
To date, there are no biomarkers of any kind available to
any of the psychiatric disorders, and perhaps establishing
those will be one of the most difficult tasks that medical
scientists will ever face, This is due to several reasons: (1)
the multifactorial characteristic of psychiatric disorders, (2)
these are multigenic disorders in which each gene has a
small effect; (3) the environment exerts a heavy influence
in the establishment of the disease. These reasons lead us to
conclude that “the biomarker” for a psychiatric condition will
never exist. At best, we will be able to identify panels or sets
of biomarkers.
Each psychiatric condition is a heterogeneous entity: for
example, bipolar disorder is one disease composed by very
opposite phases and symptoms, if we consider maniac and
depressive episodes. Moreover, there is a significant overlap
of symptoms among all psychiatric disorders. It has been
shown that up to 31% of the bipolar disorder patients may
be initially diagnosed with schizophrenia [1]. Still in this
line, there have been concerns about false-positive clinical
diagnosis due to the subjective criteria differently adopted
among clinicians [2], supporting the necessity of establishing
molecular biomarkers that could at least guide a clearer diag-
nostic decision. Nevertheless, at the current stage, diagnostic
biomarkers do not seem to be the most needed ones. First,
experienced clinicians have a good notion about the diagno-
sis, even with all concerns about subjectivity. Also, patients
suffer considerably with the uneven kind of treatments
available, making medication biomarkers more important at
this particular point of psychiatric research. Furthermore,
establishing diagnostic biomarkers at the disease onset is not
a trivial task. Recently, the first and only diagnostic test pro-
posed for schizophrenia [3], the VeriPsych, was discontinued
supporting this notion (http://www.veripsych.com/).
The most needed type of biomarkers to be applicable in
a short-term future are those which could predict or indicate
the likelihood of a successful treatment. The “one treatment
fits all” notion it is not applicable in the management of
psychiatric symptoms, since these vary significantly among
the patients according to their phenotype. For example,
one can design longitudinal studies using biological samples
collected from living patients prior to and after a certain
period of medication. Results may provide the possibility of
discovering a set of biomarker candidates to be evaluated
prior to the initiation of the treatment that could indicate
whether a given treatment is likely to be successful or not for
each particular patient. Obviously, such panel of biomarkers
must be validated in large cohorts, established from samples
collected in a noninvasive manner and employing reliable
analytical platforms.
Biomarkers to the stratification of patients are also needed
[4]. Schizophrenia, for instance, encompasses an umbrella
of disorders which may be the result of the dysfunction of
distinct molecular mechanisms triggered by environmen-
tal factors that will result, at the end of the day, in the
same condition. For example, some patients might develop
schizophrenia due to metabolic disturbances, while others
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might develop it due to inflammatory dysfunctions. In these
cases, a genetic predisposition seems to play a pivotal role,
considering the estimated heritability of schizophrenia in 80
to 85% [5], but acting through different molecular pathways.
There are still those patients which suffered a very heavy pres-
sure of the environment, which may have a more definitive
part in the establishment of the disease than genetics [6]. In
any case, each patient will have his/her particular molecular
type of schizophrenia due to their distinct phenotypes. Thus
patients must be categorized—or stratified—in a way that
distinct treatments are administered in a tailor-made fashion.
Such characterization could be done by determining molec-
ular biomarkers to each type of patient. This solution would
enhance the treatment, since each patient would be treated
according to the type of molecular dysfunction he/she has
or according to their phenotype. It has been observed a long
time ago that the strategy of treating all patients with one kind
of treatment does not seem to be the way to recover patients
and place them back to society. Although schizophrenia was
used as an example here, this strategy would be applicable for
other psychotic and affective disorders.
Last but not least, it is important to be aware of how
the concept of biomarker has been used. A biomarker is
a measurable characteristic (i.e., molecule, physical struc-
ture or observation) assessed by a validated analytical plat-
form which can indicate unequivocally a particular disease
or physiological state of an organism or even the posi-
tive/negative response of such organism to a given treatment.
The great majority of the data which has been published in
the field of biomarkers do not fulfill this definition.Therefore,
most of what we know so far are biomarker candidates or
potential biomarkers only [7]. It is necessary to consider the
different types of biomarkers proposed by the USA Food and
Drug Administration (FDA) such as exploratory biomarkers,
probably valid biomarkers, and known valid biomarkers
when performing biomarker studies [8].
This special issue of DiseaseMarkers approaches which is
the current situation regarding the discovery of biomarkers
to psychiatric disorders such as schizophrenia (Weickert
et al. 2013), depression (Labermaier et al. 2013, Carboni
2013), posttraumatic stress disorder (Schmidt et al. 2013), and
autism spectrum disorders (Voineagu and Yoo, 2013). I hope
that the information presented in this edition may be useful
to generate validation studies, develop trustworthy analytical
platforms, launch new lines of research towards personalized
medicine studies in order to approximate scientific studies
to solutions clinically applicable, or yet to approximate the
bench to the bedside.
Daniel Martins-de-Souza
References
[1] A. Gonzalez-Pinto, M. Gutierrez, F. Mosquera et al., “First
episode in bipolar disorder: misdiagnosis and psychotic symp-
toms,” Journal of Affective Disorders, vol. 50, no. 1, pp. 41–44,
1998.
[2] J. C. Wakefield, “Misdiagnosing normality: psychiatry’s failure
to address the problem of false positive diagnoses of mental
disorder in a changing professional environment,” Journal of
Mental Health, vol. 19, no. 4, pp. 337–351, 2010.
[3] E. Schwarz, R. Izmailov, M. Spain et al., “Validation of a blood-
based laboratory test to aid in the confirmation of a diagnosis
of schizophrenia,” Biomarker Insights, vol. 2010, no. 5, pp. 39–47,
2010.
[4] D.Martins-de-Souza, “Translational strategies to schizophrenia
from a proteomic perspective,” Translational Neuroscience, vol.
3, no. 3, pp. 300–302, 2012.
[5] A. G. Cardno and I. I. Gottesman, “Twin studies of schizophre-
nia: from bow-and-arrow concordances to star wars Mx and
functional genomics,” American Journal of Medical Genetics,
vol. 97, no. 1, pp. 12–17, 2000.
[6] O. D. Howes, C. McDonald, M. Cannon, L. Arseneault, J.
Boydell, and R. M. Murray, “Pathways to schizophrenia: the
impact of environmental factors,” International Journal of Neu-
ropsychopharmacology, vol. 7, supplement 1, pp. S7–S13, 2004.
[7] D. Martins-de-Souza, “Is the word ‘biomarker’ being properly
used by proteomics research in neuroscience?” The European
Archives of Psychiatry and Clinical Neuroscience, vol. 260, no. 7,
pp. 561–562, 2010.
[8] S. Bahn, E. Schwarz, L. W. Harris, D. Martins-de-Souza et al.,
“Biomarker blood tests for diagnosis and management of men-
tal disorders: focus on schizophrenia,” Revista de Psiquiatria
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